All Brands Owned by Pfizer Inc.

Prescription combination drug containing amlodipine and atorvastatin, co-promoted by Pfizer and developed for simultaneous blood pressure and cholesterol management.

Prescription COX-2 inhibitor anti-inflammatory medication for treating arthritis pain, originally developed by G.D. Searle & Company and now marketed by Pfizer.

Prescription smoking cessation medication (varenicline) developed by Pfizer, FDA-approved in 2006.

Prescription antifungal medication (fluconazole) for treating candidiasis, cryptococcal meningitis, and other fungal infections. Developed by Pfizer, FDA-approved in 1990.

Prescription anticoagulant medication (apixaban) for preventing blood clots and stroke in patients with atrial fibrillation. Co-developed and co-marketed by Bristol-Myers Squibb and Pfizer. One of the highest-grossing pharmaceutical products globally with $14.4 billion in 2025 sales.

Generic prescription folinic acid (5-formyltetrahydrofolate) used for methotrexate rescue in high-dose methotrexate chemotherapy, as a biochemical modulator of fluorouracil (5-FU) in colorectal cancer regimens including FOLFOX and FOLFIRI, and for treatment of megaloblastic anemia; originally developed by Lederle Laboratories in the 1940s and now manufactured by multiple pharmaceutical companies including Pfizer/Hospira, Teva, and Fresenius Kabi.

Brand name for atorvastatin, the world's best-selling prescription drug from 1996 to 2012, generating over $125 billion in cumulative sales. Originally developed by Parke-Davis and acquired by Pfizer in 2000. Now owned by Viatris Inc. (NASDAQ: VTRS) since November 2020. FY2025 net sales of $1.55 billion.

Brand name for pregabalin, a medication for neuropathic pain, fibromyalgia, and epilepsy. Originally developed by Pfizer, now owned by Viatris (NASDAQ: VTRS) following the 2020 Upjohn spinoff. US patent expired 2019.

Prescription calcium channel blocker medication for treating high blood pressure and angina, manufactured and marketed by Pfizer.

Merck's 23-valent pneumococcal polysaccharide vaccine (PPSV23), FDA approved in 1983 as an expansion of Merck's 14-valent formulation licensed in 1977, providing T-cell independent immune protection against 23 pneumococcal serotypes in adults aged 50 and older and high-risk individuals, now used alongside conjugate vaccines per updated CDC recommendations.

Pfizer's pneumococcal conjugate vaccine franchise, originally developed by Wyeth as Prevnar (PCV7, FDA approved February 17, 2000), succeeded by Prevnar 13 (PCV13, FDA approved February 24, 2010) and Prevnar 20 (PCV20, FDA approved June 8, 2021), one of the world's best-selling vaccines with peak annual revenues exceeding $6 billion.

Brand name for sildenafil citrate, the first oral erectile dysfunction treatment approved by the FDA in 1998. Originally developed by Pfizer, now owned by Viatris following the 2020 Upjohn spinoff and Mylan merger.

Pfizer's oral JAK inhibitor (tofacitinib) approved by the FDA in 2012 for rheumatoid arthritis and other autoimmune conditions. Subject to a strengthened black box warning since September 2021.

Brand-name azithromycin antibiotic developed by Pfizer from a compound discovered by Pliva in 1980. FDA-approved in 1991 for respiratory infections, skin infections, and sexually transmitted diseases. Pfizer is discontinuing branded Zithromax tablets as of April 2026, though generic azithromycin remains widely available.